Akebia Therapeutics, Inc. 8-K

What Happened

• On January 12, 2026, Akebia Therapeutics, Inc. issued a press release (Exhibit 99.1) announcing corporate updates tied to its Vafseo® (vadadustat) commercial business and providing an outlook on upcoming milestones, including its mid‑stage rare kidney disease pipeline as the next anticipated growth driver. The company also provided an overview of expected fourth‑quarter 2025 Vafseo net product revenue in that release.
• Akebia attached a corporate presentation as Exhibit 99.2 and said company spokespersons will present the material at meetings beginning on January 12, including investor and analyst events that coincide with the 44th Annual J.P. Morgan Healthcare Conference. The Form 8‑K furnishes these materials (Items 2.02 and 7.01) and notes they are furnished, not filed, for Exchange Act purposes. The filing is signed by John P. Butler, President and CEO.

Key Details

• Press release date: January 12, 2026 (Exhibit 99.1).
• Provided an overview of expected Q4 2025 Vafseo net product revenue (details in the press release).
• Corporate presentation attached (Exhibit 99.2) to be presented at investor/analyst meetings around the J.P. Morgan Healthcare Conference.
• Information furnished in the 8‑K is not deemed “filed” under Section 18 of the Exchange Act.

Why It Matters

• Vafseo commercial performance and the company’s Q4 2025 net revenue outlook are directly relevant to Akebia’s near‑term revenue and investor expectations.
• The mid‑stage rare kidney disease program is highlighted as the next growth driver, signaling management’s strategic focus beyond current commercial sales.
• Presentation at JPM and related investor meetings increases visibility; investors should review the press release (Exhibit 99.1) and presentation (Exhibit 99.2) for the specific revenue figures and milestone timing.